Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

David M. Brown, Peter A. Campochiaro, Robert B. Bhisitkul, Allen C. Ho, Sarah Gray, Namrata Saroj, Anthony P. Adamis, Roman G. Rubio, Wendy Yee Murahashi

Research output: Contribution to journalArticle

Abstract

Purpose: Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO). Design: Prospective, randomized, sham injection-controlled, double-masked, multicenter trial. Participants: A total of 397 patients with macular edema after BRVO. Methods: Eligible patients were randomized 1:1:1 to 6 monthly injections of 0.3 mg or 0.5 mg ranibizumab or sham injections. After 6 months, all patients with study eye best-corrected visual acuity (BCVA) ≤20/40 or central subfield thickness <250 μm were to receive ranibizumab. Patients could receive rescue laser treatment once during the treatment period and once during the observation period if criteria were met. Main Outcome Measures: The main efficacy outcome reported is mean change from baseline BCVA letter score at month 12. Additional visual and anatomic parameters were assessed. Results: Mean (95% confidence interval) change from baseline BCVA letter score at month 12 was 16.4 (14.518.4) and 18.3 (15.820.9) in the 0.3 mg and 0.5 mg groups, respectively, and 12.1 (9.614.6) in the sham/0.5 mg group (P < 0.01, each ranibizumab group vs. sham/0.5 mg). The percentage of patients who gained <15 letters from baseline BCVA at month 12 was 56.0% and 60.3% in the 0.3 mg and 0.5 mg groups, respectively, and 43.9% in the sham/0.5 mg group. On average, there was a marked reduction in central foveal thickness (CFT) after the first as-needed injection of 0.5 mg ranibizumab in the sham/0.5 mg group, which was sustained through month 12. No new ocular or nonocular safety events were identified. Conclusions: At month 12, treatment with ranibizumab as needed during months 611 maintained, on average, the benefits achieved by 6 monthly ranibizumab injections in patients with macular edema after BRVO, with low rates of ocular and nonocular safety events. In the sham/0.5 mg group, treatment with ranibizumab as needed for 6 months resulted in rapid reduction in CFT to a similar level as that in the 0.3 mg ranibizumab treatment group and an improvement in BCVA, but not to the extent of that in the 2 ranibizumab groups. Intraocular injections of ranibizumab provide an effective treatment for macular edema after BRVO. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)1594-1602
Number of pages9
JournalOphthalmology
Volume118
Issue number8
DOIs
StatePublished - Aug 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Brown, D. M., Campochiaro, P. A., Bhisitkul, R. B., Ho, A. C., Gray, S., Saroj, N., Adamis, A. P., Rubio, R. G., & Murahashi, W. Y. (2011). Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology, 118(8), 1594-1602. https://doi.org/10.1016/j.ophtha.2011.02.022